サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1794687

レム睡眠行動障害の世界市場

REM Sleep Behavior Disorders

出版日
ページ情報
英文 271 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.16円
レム睡眠行動障害の世界市場
出版日: 2025年08月20日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 271 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レム睡眠行動障害の世界市場は2030年までに16億米ドルに達する

2024年に12億米ドルと推定されるレム睡眠行動障害の世界市場は、分析期間2024-2030年にCAGR 5.0%で成長し、2030年には16億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるクロナゼパムは、CAGR 5.4%を記録し、分析期間終了時には9億6,420万米ドルに達すると予測されます。メラトニン分野の成長率は、分析期間中CAGR 3.9％と推定されます。

米国市場は3億2,380万米ドルと推定、中国はCAGR 8.0％で成長すると予測

米国のレム睡眠行動障害市場は、2024年に3億2,380万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.0%で推移し、2030年には3億1,650万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.4%と5.0%と予測されています。欧州では、ドイツがCAGR 3.2%で成長すると予測されています。

世界のレム睡眠行動障害市場- 主要動向と促進要因まとめ

レム睡眠行動障害を特徴的で複雑な神経学的状態にしているものは何か？

レム睡眠行動障害（RBD）は、レム睡眠に伴う正常な筋麻痺の喪失によって特徴づけられる睡眠時随伴症であり、その結果、鮮明でしばしば暴力的な夢を身体的に演じるようになります。この疾患は、パーキンソン病、多系統萎縮症、レビー小体型認知症などの神経変性疾患との関連から、他の睡眠障害とは一線を画しています。ほとんどの場合、RBD患者は、これらの神経疾患の認知症状や運動症状が現れるずっと前に、夢の実現行動を示すことから、RBDは早期の臨床バイオマーカーとして位置づけられています。

RBDの前駆症状としての価値が臨床的に認識されつつあることで、神経科医や睡眠専門医が患者を監視・管理する方法が再構築されつつあります。従来、RBDの認知度は低く、定期的な睡眠検査も行われていなかったため、診断が下回っていましたが、現在では、高齢者や神経変性のリスクのある患者を対象に、より系統的な調査が行われています。その典型的な症状である睡眠中の頻繁な四肢運動、発声、時には傷害は、患者の安全だけでなく、長期的な神経学的監視にも重大な意味を持っています。このため、睡眠医学、神経学、精神医学の学際的協力が一般的になり、臨床睡眠評価と長期的モニタリングの需要が高まっています。

どのような診断ツールとモニタリング技術が臨床を変革しているか？

ビデオモニタリングによる睡眠ポリグラフ検査（PSG）は、依然としてRBD診断のゴールドスタンダードです。PSGでは、筋活動、呼吸パターン、神経機能とともに、無緊張レム睡眠（RSWA）を直接観察することができます。しかし、終夜PSGは高価で時間がかかり、資源に制約のある医療システムでは拡張性がないです。この制限により、アクチグラフィ、筋電図、およびオーディオビジュアルコンポーネントを使用して、外来環境でRBD症状をスクリーニングするポータブル家庭用睡眠モニタリングシステムの開発が加速しています。

人工知能の睡眠診断への統合もこの分野を前進させています。AI主導のプラットフォームは現在、睡眠段階を自動的にスコア化し、RSWAを検出し、患者の運動パターンを高い精度で分析することができます。こうした技術は、リスクのある集団を事前にスクリーニングし、大規模な疫学研究を促進する上で特に価値があります。バイオマーカー研究もまた、急速に進歩している分野です。脳脊髄液、唾液タンパク質、末梢皮膚生検におけるαシヌクレインレベルの研究は、RBDを確認し、疾患の進行を予測するための非侵襲的方法への扉を開いています。PETやDaT SPECTスキャンなどの機能的画像診断ツールも同様に、パーキンソン症候群に関連する脳領域の不顕性変化を同定することにより、早期診断をサポートしています。

症状や病態に対応するために、治療法はどのように進化しているのでしょうか？

現在、RBDの治療は主に症状の緩和に焦点が当てられています。ベンゾジアゼピンの一種であるクロナゼパムは、レム睡眠中の異常な運動を抑制し、睡眠の連続性を改善するために長い間使用されてきました。しかし、認知障害や日中の眠気などの副作用が懸念されるため、代替薬の検討が進められています。特に高用量のメラトニンは、その良好な安全性プロファイルと夢の出現を抑制する能力から注目されています。また、有効性と安全性のバランスをとるために、クロナゼパムの低用量をメラトニンと同時に投与する併用療法に反応する患者もいます。

現在進行中の臨床試験では、RBDの神経変性基盤を標的とした新規の薬理学的介入が検討されています。シヌクレインの凝集を調節し、ミトコンドリア機能を増強し、神経炎症を抑制することを目的とした治験薬が、疾患修飾と症状抑制の両方の目的で試験されています。さらに、寝室から危険物を取り除く、ベッドレールを設置する、睡眠衛生を改善するなどのライフスタイルの適応は、傷害リスクの低減に重要な役割を果たしています。遠隔医療プラットフォームはまた、特に高齢で動けない患者の間で、遠隔フォローアップ、コンプライアンス追跡、症状悪化の早期発見を提供するために採用されています。

レム睡眠行動障害市場の成長を促進する要因は？

レム睡眠行動障害市場の成長の原動力は、神経変性疾患の有病率の上昇、睡眠時随伴症に対する認知度の向上、診断能力の拡大、臨床研究資金の急増です。世界人口の高齢化に伴い、パーキンソン病やその他のα-シヌクレイン病の罹患率が増加しており、RBDを呈する可能性のある人の数が増加しています。神経変性疾患への早期介入の推進により、RBDはセンチネル疾患として位置付けられ、臨床的焦点と患者支援活動が強化されています。

ヘルスケアのインフラ整備、特に睡眠医療は、睡眠ポリグラフ検査、神経科医による診察、集学的治療センターへのアクセスを向上させ、市場を支えています。さらに、公的・民間研究資金により、RBDを予測バイオマーカーとして探索する大規模な縦断的研究が可能になり、診断薬や治療薬の技術革新に拍車をかけています。業界各社は、アクセシビリティのギャップを埋めるために、ウェアラブル診断ツールやAIを搭載したソフトウェア・ソリューションを積極的に開発しています。規制当局がRBD関連の診断薬や治療法の承認経路を促進することに関心を示していることから、市場は今後10年間で持続的に拡大する見通しです。

セグメント

薬物タイプ（クロナゼパム、メラトニン、その他の薬物タイプ）;エンドユーザー（病院エンドユーザー、診療所エンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • Advanced Brain Monitoring, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Becton, Dickinson and Company
  • BMC Medical Co., Ltd.
  • Bristol-Myers Squibb Company
  • Cadwell Industries, Inc.
  • Cipla Inc.
  • Compumedics Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Fisher & Paykel Healthcare Limited
  • GlaxoSmithKline plc（GSK）
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Private Limited
  • Koninklijke Philips N.V.（Philips Healthcare）
  • Merck & Co., Inc.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Novartis AG
  • Pfizer Inc.
  • Reddy's Laboratories Ltd.
  • ResMed Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP37889

Global REM Sleep Behavior Disorders Market to Reach US$1.6 Billion by 2030

The global market for REM Sleep Behavior Disorders estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. Clonazepam, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$964.2 Million by the end of the analysis period. Growth in the Melatonin segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$323.8 Million While China is Forecast to Grow at 8.0% CAGR

The REM Sleep Behavior Disorders market in the U.S. is estimated at US$323.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$316.5 Million by the year 2030 trailing a CAGR of 8.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Global REM Sleep Behavior Disorders Market - Key Trends & Drivers Summarized

What Makes REM Sleep Behavior Disorder a Distinctive and Complex Neurological Condition?

REM Sleep Behavior Disorder (RBD) is a parasomnia characterized by a loss of the normal muscle paralysis that accompanies REM sleep, resulting in individuals physically acting out vivid, and often violent, dreams. This condition stands apart from other sleep disorders due to its association with neurodegenerative diseases such as Parkinson’s disease, multiple system atrophy, and dementia with Lewy bodies. In most cases, patients with RBD exhibit dream enactment behavior long before cognitive or motor symptoms of these neurological conditions manifest, positioning RBD as an early clinical biomarker.

The growing clinical recognition of RBD’s prodromal value is reshaping the way neurologists and sleep specialists monitor and manage patients. Traditionally underdiagnosed due to limited awareness and lack of routine sleep studies, RBD is now being investigated more systematically in aging populations and individuals at risk of neurodegeneration. Its typical manifestation-frequent limb movements, vocalizations, and sometimes injuries during sleep-has significant implications not only for patient safety but also for long-term neurological surveillance. This has resulted in increased demand for clinical sleep assessments and longitudinal monitoring, with interdisciplinary collaboration between sleep medicine, neurology, and psychiatry becoming more commonplace.

Which Diagnostic Tools and Monitoring Technologies Are Transforming Clinical Practices?

Polysomnography (PSG) with video monitoring remains the gold standard for RBD diagnosis. PSG enables direct observation of REM sleep without atonia (RSWA), along with muscle activity, respiratory patterns, and neurological function. However, full-night PSG is expensive, time-consuming, and not scalable in resource-constrained health systems. This limitation has accelerated the development of portable home sleep monitoring systems that use actigraphy, electromyography, and audio-visual components to screen for RBD symptoms in ambulatory settings.

The integration of artificial intelligence into sleep diagnostics is also advancing the field. AI-driven platforms can now automatically score sleep stages, detect RSWA, and analyze patient movement patterns with high accuracy. These technologies are especially valuable in pre-screening at-risk populations and facilitating large-scale epidemiological studies. Biomarker research is another area of rapid progress. Investigations into alpha-synuclein levels in cerebrospinal fluid, salivary proteins, and peripheral skin biopsies are opening doors to non-invasive methods for confirming RBD and forecasting disease progression. Functional imaging tools such as PET and DaT SPECT scans are likewise supporting early diagnosis by identifying subclinical changes in brain regions associated with Parkinsonian syndromes.

How Is the Treatment Landscape Evolving to Address Symptomatology and Underlying Pathologies?

Currently, the treatment of RBD is focused primarily on symptom mitigation. Clonazepam, a benzodiazepine, has long been used to suppress abnormal movements during REM sleep and improve sleep continuity. However, concerns about side effects, including cognitive impairment and daytime drowsiness, have prompted exploration of alternatives. Melatonin, particularly in high doses, has gained prominence for its favorable safety profile and ability to reduce dream enactment. Some patients also respond to combined therapies, where lower doses of clonazepam are administered alongside melatonin to balance efficacy and safety.

Ongoing clinical trials are now exploring novel pharmacological interventions targeting the neurodegenerative underpinnings of RBD. Investigational drugs aimed at modulating synuclein aggregation, enhancing mitochondrial function, or reducing neuroinflammation are being tested for both disease modification and symptomatic control. Additionally, lifestyle adaptations-such as removing hazardous objects from bedrooms, installing bed rails, and improving sleep hygiene-play a critical role in reducing injury risk. Telehealth platforms are also being adopted to offer remote follow-ups, compliance tracking, and early detection of symptom exacerbation, particularly among elderly and immobile patients.

What Factors Are Driving the Growth of the REM Sleep Behavior Disorders Market?

The growth in the REM Sleep Behavior Disorders market is driven by rising neurodegenerative disease prevalence, improved awareness of parasomnias, expanded diagnostic capabilities, and a surge in clinical research funding. As global populations age, the incidence of Parkinson’s disease and other alpha-synucleinopathies is increasing, raising the number of individuals likely to present with RBD. The push for early intervention in neurodegenerative conditions has positioned RBD as a sentinel disorder, resulting in greater clinical focus and patient outreach efforts.

Healthcare infrastructure improvements, particularly in sleep medicine, are supporting the market by increasing access to polysomnography, neurologist consultations, and multidisciplinary care centers. Furthermore, public and private research funding is enabling large-scale longitudinal studies that explore RBD as a predictive biomarker, fueling innovation in diagnostics and therapeutics. Industry players are actively developing wearable diagnostic tools and AI-powered software solutions to fill the accessibility gap. With regulators showing interest in facilitating approval pathways for RBD-related diagnostics and treatments, the market is positioned for sustained expansion over the next decade.

SCOPE OF STUDY:

The report analyzes the REM Sleep Behavior Disorders market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Clonazepam, Melatonin, Other Drug Types); End-Use (Hospitals End-Use, Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Advanced Brain Monitoring, Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Becton, Dickinson and Company
  • BMC Medical Co., Ltd.
  • Bristol-Myers Squibb Company
  • Cadwell Industries, Inc.
  • Cipla Inc.
  • Compumedics Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Fisher & Paykel Healthcare Limited
  • GlaxoSmithKline plc (GSK)
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Private Limited
  • Koninklijke Philips N.V. (Philips Healthcare)
  • Merck & Co., Inc.
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Novartis AG
  • Pfizer Inc.
  • Reddy's Laboratories Ltd.
  • ResMed Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • REM Sleep Behavior Disorders - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Recognition of Sleep Health as a Medical Priority Expands Clinical Focus
    • Rising Geriatric Population Drives Prevalence of REM Sleep Behavior Disorders
    • Improved Access to Sleep Diagnostics Strengthens Early Detection Rates
    • Integration of Polysomnography and Wearables Accelerates Diagnosis Efficiency
    • Increasing Linkages Between Neurodegenerative Disorders and REM Behavior Issues Spur Research
    • Innovation in Non-Invasive Therapies Promotes Patient Acceptance and Treatment Compliance
    • Pharmaceutical Pipeline Developments Throw the Spotlight on Novel Therapeutic Agents
    • Expansion of Sleep Clinics and Centers Supports Specialist Treatment Options
    • Development of Digital Sleep Monitoring Platforms Enhances Patient Monitoring Accuracy
    • Use of AI in Sleep Pattern Analysis Generates Predictive Insight Opportunities
    • Patient Advocacy and Awareness Campaigns Accelerate Diagnosis and Intervention
    • Regulatory Approvals for Targeted Drugs Stimulate Industry Investment
    • Collaborations Between Neurologists and Sleep Specialists Foster Holistic Care Models
    • Genetic and Biomarker Research Improves Understanding of Underlying Mechanisms
    • Adoption of Telehealth Platforms Enables Broader Reach of Sleep Disorder Therapies
    • Clinical Trials Focused on Parkinson's Disease Patients Expand Data on REM Disruptions
    • Expansion of Reimbursement Coverage Encourages Wider Treatment Uptake
    • Inclusion of Sleep Modules in Wellness Platforms Broadens Consumer Awareness
    • Multimodal Treatment Approaches Drive Innovation in Care Delivery
    • Public Health Emphasis on Sleep Quality Positions REM Disorders as High-Priority Segment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World REM Sleep Behavior Disorders Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for REM Sleep Behavior Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Clonazepam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Clonazepam by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Clonazepam by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Melatonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Melatonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Melatonin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for REM Sleep Behavior Disorders by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for REM Sleep Behavior Disorders by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for REM Sleep Behavior Disorders by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for REM Sleep Behavior Disorders by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • REM Sleep Behavior Disorders Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for REM Sleep Behavior Disorders by Drug Type - Clonazepam, Melatonin and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for REM Sleep Behavior Disorders by Drug Type - Percentage Breakdown of Value Sales for Clonazepam, Melatonin and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for REM Sleep Behavior Disorders by End-Use - Hospitals End-Use, Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for REM Sleep Behavior Disorders by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION